A retrospective study compared progression-free and overall survival of hyperthermic intraperitoneal chemotherapy with conventional intraperitoneal chemotherapy in patients with ovarian cancer.
Please provide your email address to receive an email when new articles are posted on . The addition of intraperitoneal paclitaxel to systemic capecitabine and oxaliplatin appeared to benefit patients ...
Because cytotoxicity is one of the major hurdles in the application of many transfection agents, an important feature of our cationic liposome is its low toxicity for cells at the concentrations ...
Please provide your email address to receive an email when new articles are posted on . Adding hyperthermic intraperitoneal chemotherapy to cytoreductive surgery did not significantly prolong PFS or ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...
Cancers originating from organs in the peritoneal cavity (e.g., ovarian, pancreatic, colorectal, gastric and liver) account for approximately 250,000 new cancer cases annually in the USA. Peritoneal ...
Validity of the Patient-Reported Outcome Measurement Information System (PROMIS) Sexual Interest and Satisfaction Measures in Men Following Radical Prostatectomy Compared with CRSa, CRS-HIPEC improved ...
HIPEC surgery is a promising treatment option for patients with certain abdominal cancers. Surgical oncologist Erin Ward, MD, discusses which patients would be best candidates for HIPEC, explains why ...
WEST PHILADELPHIA (WPVI) -- Chemotherapy is a lifesaver in cancer treatment. But an IV isn't always the best way to deliver it. A different technique is helping make a difference for some abdominal ...
CHICAGO — Intraperitoneal (IP) chemotherapy is now an alternative to intravenous (IV) administration that "must be discussed" for women with cytoreduced ovarian cancer, several experts said here at ...
Your treatment depends on several factors. These include where the cancer is, and your general health. You might not start treatment straight away. Your doctor closely monitors your cancer in case you ...